 |
| Editors' Choice: Story of the Week | |
 |
Commentary
2009 Oct 21, Lee Schwartzberg, MD, PhD, Editor-in-Chief
Sorting breast cancer into distinct subtypes, as defined by an intrinsic gene set, allows for the characterization of different prognostic and predictive profiles for each subtype. Investigators from CALGB retrospectively studied the subtypes through tissue microarrays and determined that patients with luminal A breast cancers (ER+, HER2–, low proliferation) derived no benefit from the addition of paclitaxel to AC as adjuvant therapy. Other subgroups, including patients with basal, luminal B, and HER2+ tumors, did benefit from adjuvant paclitaxel, however. These results are consistent with data sets using other genetic profiles demonstrating the effectiveness of less aggressive chemotherapy in highly hormone-responsive breast cancer. Such analyses allow us to refine our approach to adjuvant therapy, selecting more specific regimens and reducing toxicity in patient subgroups who will not benefit from more extensive treatment.
|
Paclitaxel Does Not Help Women With Luminal A Breast Cancer
Elsevier Global Medical News, 2009 Oct 15, S Boschert
EXPERT COMMENTARY
Women with the most common, least aggressive subtype of breast cancer do not benefit from the addition of paclitaxel to adjuvant chemotherapy.
|
| Journal Scans | More » |
|
Venous Thromboembolism in Lymphoma: How Effectively Are We Treating Patients?
Am J Clin Oncol, 2009 Oct 1, AA Muslimani, et al
Warfarin treatment was linked with a 30% rate of recurrent thrombosis and a 13% rate of major bleeding in lymphoma patients.
|
Trastuzumab Plus Anastrozole in Postmenopausal HER2+/HR+ Metastatic Breast Cancer
J Clin Oncol, 2009 Sept 28, B Kaufman, et al
Results from the TAnDEM study showed improved PFS with anastrozole + trastuzumab vs anastrozole alone.
|
Indwelling Catheters for the Management of Refractory Malignant Ascites
J Pain Symptom Manage, 2009 Sept 1, ND Fleming, et al
Indwelling IP catheters are safe and effective in the palliative management of malignant ascites, and are not associated with overly high infection rates.
|
| What Patients Are Reading | More » |
|
Long-Term Thiopurine Treatment for IBD Ups the Risk of Lymphoma
As Reported by HealthDay News, 2009 Oct 19
People with IBD who receive immunosuppressive therapy with thiopurines may raise their risk of developing malignant lymphomas of viral origin.
|
Drug Crosses Blood-Brain Barrier and Shrinks Brain Tumors
As Reported by Reuters, 2009 Oct 18
High doses of ANG1005 shrank primary and metastatic brain tumors in 2 early-phase studies involving 100 patients.
|
Chemotherapy-Related Fatigue Is Helped by Varying Intensities and Types of Exercise
As Reported by HealthDay News, 2009 Oct 14
Even in patients with advanced cancer, exercise of varying intensity and interventions such as massage relieved chemotherapy-related fatigue.
|
Minimally Invasive Radical Prostatectomy Not Superior to Open Surgery
As Reported by the LA Times, 2009 Oct 14
Urinary incontinence and erectile dysfunction were more common after minimally invasive than after open radical prostatectomy.
|
|
| | |
| EDITORIAL BOARD
Our physician editors collaborate weekly to choose the website's top story.
VISIT SITE
| |
|
|
| | |
| ASCO BREAST
Read conference news from this year's multidisciplinary event.
| |
|
|
| | |
| ECCO/ESMO 2009
Conference news plus interviews with ECCO/ESMO officers.
| |
|
|
| | |
| MM CME
Earn valuable credits by participating in this case-based online program in multiple myeloma.
| |
|
|
| | |
| COMMENTARY
Dr. David Henry focuses on some of the studies presented at ECCO/ESMO that may change or influence practice.
VISIT SITE
| |
|
|
| | |
| PRACTICE MANAGEMENT
Key information on everything from legal affairs to new technologies.
VISIT SITE
| |
|
|
|
The Latest Oncology Intelligence
